Complement activation and corticosteroid therapy in the development of the adult respiratory distress syndrome.
Fifty-nine patients in septic shock were observed for the development of the adult respiratory distress syndrome (ARDS) prior to and after receiving either 30 mg/kg methylprednisolone sodium succinate, 6 mg/kg dexamethasone sodium phosphate or no steroid. Serum levels of C3, C4 and Factor B allowed classification of 42 patients by activation of complement pathways. Despite a trend toward patients with severe septic shock who activate the alternative pathway being protected from the development of ARDS, complement pathway determination did not allow prediction of the development of ARDS and steroid pretreatment did not influence complement levels or prevent ARDS.
D003167:Complement Activation; D003907:Dexamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use*; D008875:Middle Aged; D012128:Respiratory Distress Syndrome / Q000209:etiology* / Q000517:prevention & control; D012772:Shock, Septic / Q000150:complications
C004180:dexamethasone 21-phosphate; D008776:Methylprednisolone Hemisuccinate; D003907:Dexamethasone; D008775:Methylprednisolone